Original Research

Ongoing activities to influence the prescribing of proton pump inhibitors within the Scottish National Health Service: their effect and implications

Published in: Volume 7 / Year 2018 / Issue 4
Author(s): , , , , , , ,
Page: 142-51

Author byline as per print journal: Professor Brian Godman, BSc, PhD; Amanj Kurdi, PhD; Holly McCabe, MSc; Sean MacBride-Stewart, MSc; Axel Leporowski, MD; Simon Hurding, MD; Professor Marion Bennie, MSc; Professor… Read More »

In vitro analytical and antibiotic comparison of generic moxifloxacin against E. coli and S. aureus bacteria strains

Published in: Volume 7 / Year 2018 / Issue 3
Author(s): , ,
Page: 121-6

Introduction: Moxifloxacin is a quinolone antibiotic often used to treat infections caused by Gram-positive bacteria that have developed resistance in Colombia in recent years. Objective: To evaluate the concentration of… Read More »

Implementing a treatment registry for a biosimilar: continuous safety surveillance of the biosimilar Bevax® (bevacizumab) in Argentina

Published in: Volume 7 / Year 2018 / Issue 3
Author(s): , , , , ,
Page: 111-20

Introduction and study objectives: Benefit-risk evaluations are essential throughout the life cycle of a drug to guarantee therapeutic efficacy for the authorized indications without an unacceptable incidence of adverse effects.… Read More »

Extended stability of a biosimilar of trastuzumab (CT-P6) after reconstitution in vials, dilution in polyolefin bags and storage at various temperatures

Published in: Volume 7 / Year 2018 / Issue 3
Author(s): , ,
Page: 101-10

Author byline as per print journal: Victoire Vieillard, PharmD; Professor Alain Astier, PharmD, PhD; Muriel Paul, PharmD Objectives: This study assessed the long-term stability of the trastuzumab biosimilar CT-P6 (Herzuma®, Biogaran)… Read More »

Patient-reported outcome measures in phase III trials of LY2963016 insulin glargine and reference insulin glargine products: ELEMENT 1 and ELEMENT 2

Published in: Volume 7 / Year 2018 / Issue 2
Author(s): , , , , , ,
Page: 56-62

Author byline as per print journal: Magaly Perez-Nieves1, MPH, PhD; Robyn K Pollom1, ANP; Ran Duan1, PhD; Samaneh Kabul1, PharmD; Amy M DeLozier1, MPH; Puneet Kaushik2, MPharm; Liza L Ilag1,… Read More »

Analysis of Drug Master Files registered in Japan: aiming for a stable supply of active pharmaceutical ingredients

Published in: Volume 7 / Year 2018 / Issue 1
Author(s): ,
Page: 8-13

Introduction/Study objectives: A stable supply of active pharmaceutical ingredients (APIs) is indispensable for a stable supply of finished pharmaceutical products (FPPs). API manufacturers generally register API information as a Drug… Read More »

Pharmacy-mediated substitution of biosimilars – a global survey benchmarking country substitution policies

Published in: Volume 6 / Year 2017 / Issue 4
Author(s): , ,
Page: 157-64

Introduction/Study objectives: Between March and May 2017, Pfizer conducted an internal global survey of 82 countries examining biosimilar pharmacy-mediated substitution to understand and benchmark the global policy landscape. Methods: Pfizer… Read More »

A survey of Australian prescribers’ views on the naming and substitution of biologicals

Published in: Volume 6 / Year 2017 / Issue 3
Author(s): ,
Page: 107-13

Author byline as per print journal: Stephen P Murby, FRSA; Michael S Reilly, Esq Introduction: As the number of biosimilar approvals in Australia increases, it is important to build on the… Read More »

Do pricing and usage-enhancing policies differ between biosimilars and generics? Findings from an international survey

Published in: Volume 6 / Year 2017 / Issue 2
Author(s): ,
Page: 79-88

Introduction/Study objective: This paper aims to survey the policies implemented by European countries for pricing and promoting the use of biosimilar medicines and to explore similarities and differences with policies… Read More »

What pricing and reimbursement policies to use for off-patent biologicals in Europe? – results from the second EBE biological medicines policy survey

Published in: Volume 6 / Year 2017 / Issue 2
Author(s): , ,
Page: 61-78

Author byline as per print journal: Jean-Baptiste Reiland, MSc; Barbara Freischem; Alexander Roediger, MA Introduction/Study objective Biosimilar policies with a focus on uptake have received a lot of attention at national… Read More »

Page 1 of 4 1 2 3 4 Next »
Go Back Print